ROCKVILLE, Md., Nov. 09, 2017 — Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its 2017 R&D Day for the investment community on Thursday, November 16, 2017 from 9:00 a.m. – 12:00 p.m. ET in New York, NY.
Sucampo will highlight its two Phase 3 rare and orphan drug programs in Niemann-Pick Disease Type C1 (NPC-1) and Familial Adenomatous Polyposis (FAP). Management will be joined by three distinguished expert physicians who will present on the significance of these rare diseases and provide perspective on Sucampo’s development programs:Dr. Carol Burke – Director of the Section of Polyposis at the Sanford R. Weiss M.D. Center for Hereditary Colorectal Neoplasia and Vice Chair of the Gastroenterology and Hepatology department at the Cleveland ClinicDr. Paul Gissen – Head of the Genetics and Genomic Medicine Academic Programme at the University College London, Consultant in Inherited Metabolic Diseases at Great Ormond Street Hospital for Children, London, UK and a Wellcome Trust Senior Research FellowDr. Daniel Ory – Professor of Medicine, Cell Biology and Physiology and the Alan A. And Edith L. Wolff Professor of Cardiology at the Washington University School of MedicineIn-person attendance requires advance registration. Please note that attendance is limited to members of the investment community. Please email [email protected] for further information.A live webcast of the event will be accessible through the Investors section of the company’s website at http://www.sucampo.com/investors/events-presentations/. Members of the investment community interested in joining the webcast should log on 30 minutes before the teleconference begins to download any software required. A replay of the webcast will also be available and archived on the site.About Sucampo Pharmaceuticals, Inc.Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of highly specialized medicines. Sucampo has a late-stage pipeline of product candidates in clinical development for orphan disease areas, including VTS-270, a 2-hydroxypropyl-beta-cyclodextrin product with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2b/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1, a rare progressive genetic disorder. VTS-270 also has been granted breakthrough therapy designation in the U.S. Sucampo has an exclusive option for the North American rights to CPP-1x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. The company has two marketed products – AMITIZA and RESCULA. For more information, please visit www.sucampo.com.The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals).Twitter LinkedInSucampo Forward-Looking StatementThis press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding financial results, product development, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo's ability to accurately predict future market conditions; Sucampo’s ability to successfully integrate the operations of acquired businesses; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the effects of competitive products on Sucampo’s products; and the exposure to litigation and/or regulatory actions.No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's most recent Form 10-K as filed with the Securities and Exchange Commission on March 8, 2017, as well as its filings with the Securities and Exchange Commission on Forms 8-K and 10-Q since the filing of the Form 10-K, all of which Sucampo incorporates by reference.Contact:
Sucampo Pharmaceuticals, Inc.
Senior Vice President, Investor Relations and Corporate Affairs
Latest posts by Brad Bennett (see all)
- Hovnanian Enterprises Announces First Quarter Fiscal Year 2018 Earnings Release and Conference Call - February 22, 2018
- Carnival Paradise Undergoing Massive, Month-Long Renovation That Will Add New Water Park, New Cabins, Balconies To Existing Staterooms And Exciting Food And Beverage Innovations - February 22, 2018
- Global Teletherapy Now Hiring School Psychologists and Social Workers - February 22, 2018